Details for Patent: 8,999,970
✉ Email this page to a colleague
Summary for Patent: 8,999,970
Title: | Administration of an anti-obesity compound to individuals with renal impairment |
Abstract: | The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. |
Inventor(s): | Anderson; Christen M. (Encinitas, CA), Shanahan; William R. (Del Mar, CA) |
Assignee: | Arena Pharmaceuticals, Inc. (San Diego, CA) |
Application Number: | 13/511,639 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,999,970 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,999,970
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,999,970
PCT Information | |||
PCT Filed | August 31, 2011 | PCT Application Number: | PCT/US2011/049936 |
PCT Publication Date: | March 08, 2012 | PCT Publication Number: | WO2012/030939 |
International Family Members for US Patent 8,999,970
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2011296015 | ⤷ Try a Trial | |||
Australia | 2016200860 | ⤷ Try a Trial | |||
Australia | 2018200108 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |